CXI Healthcare to Issue 49.5% Dilutive Rights Offering to Largest Shareholder, Raising Concerns for Shareholder Value

CXI Healthcare has decided on a third-party allotment of 3.7 million shares to its largest shareholder LIN JINSHENG, raising approximately 7.23 billion KRW.
This issuance will increase total shares from about 7.47 million to 11.17 million, resulting in a 49.5% dilution of existing shareholder value.
The issue price of 1,955 KRW is based on the last closing price prior to trading suspension with no discount, but the dilution impact is severe.
The funds will be used for operating expenses including tea plantation acquisition, labor costs, and marketing, reflecting the company's urgent financial needs.
New shares are subject to a one-year lock-up period, restricting immediate sale.
The fact that the counterparty is the largest shareholder raises governance concerns.
[AI Summary]CXI Healthcare conducts a highly dilutive capital increase of about 49.5% to raise 7.23 billion KRW for operating funds. Despite the lock-up and sole participation by the largest shareholder, the near-doubling of outstanding shares poses significant risk to existing shareholder value. Investors should be cautious of potential short-term price decline and long-term earnings dilution.